Social Determinants of Health (SDOH) and Cognition: A Scoping Review

by Clinical Neuropsychologist Online | Thursday, October 8, 2026 | Dementia

Dementia, Ahead of Print. To map the evidence of disparities in cognition across different social determinants of health (SDOH), examine how SDOH are measured in the context of research on cognitive outcomes and identify knowledge gaps. PubMed, the Cochrane Library,...

Network‐dependent remote effects and local tau burden jointly shape neuronal dysfunction in Alzheimer’s disease

by Clinical Neuropsychologist Online | Thursday, October 8, 2026 | Dementia

Abstract BACKGROUND Tau pathology in Alzheimer’s disease (AD) propagates along the brain’s connectome, yet the mechanisms by which tau drives neuronal dysfunction remain unclear. We hypothesized that dysfunction primarily emerges in regions close to...

The value of timely treatment with anti‐amyloid therapy for Alzheimer’s disease

by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia

Abstract INTRODUCTION Anti-amyloid therapies can slow Alzheimer’s disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti-amyloid treatment for...

Genetic evidence supports a cortical neuroprotective role of GLP‐1 receptor activation in Alzheimer’s disease: A drug‐target Mendelian randomization study

by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia

Abstract INTRODUCTION Whether glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) activation lowers Alzheimer’s disease (AD) risk via peripheral metabolic improvement or direct neuroprotection remains unclear. METHODS Using blood and brain-cortex cis-acting...

miR‐214‐3p and NCKAP1: A microglial functional dimension of Alzheimer’s progression

by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia

Abstract INTRODUCTION Biological Alzheimer’s disease (AD) pathology does not fully explain the marked heterogeneity in clinical severity or progression. We investigated whether patient-derived induced microglia-like cell (iMG) profiles capture a functional...

Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies

by Clinical Neuropsychologist Online | Wednesday, October 7, 2026 | Dementia

Abstract INTRODUCTION Anti-amyloid antibody clinical trials with a high proportion of participants reaching treatment-related amyloid clearance (TRAC) had positive clinical outcomes. We evaluated the aducanumab phase 3 program to determine whether TRAC during the...